Author Archives: Admin

The Neuropad Test: Assessing Diabetic Peripheral Neuropathy at the Point of Care

Diabetic peripheral neuropathy (DPN) is one of the most prevalent and debilitating complications of diabetes mellitus, affecting up to 50% of people living with the condition over their lifetime. It is a major driver of foot ulceration, lower limb amputation, and cardiovascular autonomic dysfunction, carrying significant burdens for both patients and healthcare systems. Early, accurate detection is therefore critical — yet standard neurological assessments can be time-consuming, require specialist equipment, and are poorly suited to routine clinical settings. Into this gap has stepped the Neuropad, a simple, point-of-care indicator test that detects sudomotor (sweat gland) dysfunction as a proxy marker for small autonomic nerve fibre damage. Understanding how it works, what the evidence says, and where it fits in clinical practice is essential for clinicians managing diabetes.

How Neuropad Works

Neuropad is a small adhesive plaster developed by TRIGOcare International and designed for application to the plantar (sole) surface of the foot. The pad contains anhydrous cobalt (II) chloride — a blue compound that undergoes a well-characterised colour change when it absorbs water. When applied to the skin for ten minutes, a normal sudomotor response causes the pad to turn from blue to pink, reflecting adequate moisture from sweat glands. An abnormal or incomplete colour change — the pad remaining blue or turning only partially pink — indicates reduced or absent sweating, which is a hallmark of small autonomic C-fibre dysfunction.

The test is patented as a ten-minute screening tool for early detection of diabetic foot syndrome. It is non-invasive, painless, and requires no specialised equipment beyond the plaster itself, making it readily deployable in primary care, diabetes clinics, or even as a patient self-test at home. At a list price of approximately £7.28 per test (as assessed by NICE), it is substantially more affordable than nerve conduction studies or skin biopsy.

The Scientific Basis: Sudomotor Dysfunction in Neuropathy

Sweating in the feet is regulated by postganglionic cholinergic sympathetic nerve fibres — small, unmyelinated C-fibres that are among the earliest structures damaged in diabetic neuropathy. Sudomotor dysfunction therefore represents an early and sensitive marker of neuropathic change, often preceding clinical symptoms and detectable deficits in large-fibre tests such as vibration perception or nerve conduction velocity.

This biological rationale lends Neuropad particular relevance to the detection of small-fibre neuropathy — a form of DPN that traditional assessments poorly capture. Established tools such as the Neuropathy Disability Score (NDS) and nerve conduction studies (NCS) predominantly assess large myelinated fibres, and can miss early small-fibre involvement entirely.

Diagnostic Performance

The evidence base for Neuropad has grown substantially over the past two decades, with numerous clinical studies examining its sensitivity, specificity, and correlation with established neuropathy markers.

A landmark 2008 study by Quattrini et al., published in Diabetologia, evaluated 57 diabetic patients using Neuropad alongside quantitative sensory testing, autonomic function assessments, and intra-epidermal nerve fibre density from skin biopsy. The results demonstrated meaningful correlations between Neuropad responses and the NDS, neuropathic symptom scores, cold detection thresholds, and deep-breathing heart rate variability — reflecting both somatic and autonomic neuropathic involvement.

Subsequent studies have further characterised its performance profile. Across assessments against large-fibre neuropathy markers — such as the NDS and peroneal motor nerve conduction velocity — Neuropad demonstrates high sensitivity (typically 80–95%) but moderate specificity (50–70%). This pattern makes it well-suited as a screening tool: a normal result reliably reduces the likelihood of clinically significant neuropathy, but an abnormal result warrants further investigation.

Importantly, diagnostic accuracy is meaningfully improved when Neuropad is assessed against small-fibre measures. A 2014 study by Ponirakis and colleagues found that, compared with corneal nerve fibre length — a sensitive marker of small-fibre damage assessed by corneal confocal microscopy — Neuropad achieved a sensitivity of 83% and specificity of 80%, with an area under the ROC curve (AUC) of 85%. This outperformed its performance against both the NDS (AUC 66%) and peroneal motor nerve conduction velocity (AUC 70%), underscoring the test’s specific utility for small C-fibre assessment.

An important refinement involves moving beyond simple binary (pink/blue) interpretation to quantifying the rate of colour change. A study examining automated image analysis (Sudometrics) demonstrated that continuous colour-change output substantially improved diagnostic accuracy, achieving high sensitivity and specificity for autonomic dysfunction (91% and 83% respectively) and small-fibre neuropathy (88% and 78%), compared with the weaker specificity of the categorical reading alone.

Research has also established Neuropad’s reproducibility. A study in 142 type 2 diabetic patients found a highly significant correlation (r = 0.91) between repeat measurements of time to complete colour change, indicating strong test-retest reliability.

Autonomic Neuropathy and Cardiovascular Risk

Beyond peripheral neuropathy, Neuropad has been evaluated as a tool for detecting cardiovascular autonomic neuropathy (CAN) — a potentially life-threatening condition associated with silent myocardial ischaemia, arrhythmia, and increased mortality. Time to complete colour change correlates significantly with the Valsalva ratio, a standard autonomic function test, as well as with symptoms of DPN and postural hypotension. A cut-off of fifteen minutes for complete colour change has been identified as an optimal threshold, improving specificity for both CAN and DPN without compromising sensitivity.

Given that CAN often goes undetected until advanced stages, the ability of a simple plaster to prompt further autonomic evaluation is clinically meaningful.

Limitations and Clinical Considerations

Neuropad is not without limitations. Its moderate specificity, particularly against large-fibre assessments, means a positive result should not be used in isolation for diagnosis. Environmental factors — ambient temperature, skin moisture, and humidity — may influence the rate and completeness of colour change, adding variability to qualitative readings. Age, BMI, renal function, and alcohol use have also been identified as potential confounders of sudomotor function independent of glycaemic status.

In elderly populations with diabetes or pre-diabetes, the KORA F4 survey found reasonable sensitivity but low specificity for polyneuropathy diagnosis, with a positive predictive value as low as 33.6%. This supports positioning Neuropad as a triage or exclusion test rather than a standalone diagnostic.

NICE evaluated Neuropad under its Medical Technologies Guidance programme (MTG38, 2018), recommending it as an option for detecting early DPN, particularly in settings where more specialised testing is unavailable. The guidance acknowledged its ease of use and potential value in identifying patients who require further assessment.

Conclusion

The Neuropad test occupies a valuable niche in the clinical assessment of diabetic neuropathy. By providing a simple, inexpensive, and non-invasive window into sudomotor and small C-fibre function, it enables early detection of neuropathic changes that traditional large-fibre assessments routinely miss. Its high sensitivity makes it particularly effective as a screening and exclusion tool, and its performance improves markedly when interpreted quantitatively or benchmarked against small-fibre measures. While it should not replace comprehensive neurological evaluation, Neuropad represents a practical and evidence-based addition to the diabetic foot assessment toolkit — one that can meaningfully support earlier intervention and reduce the risk of serious complications.

Treatment of a Navicular Stress Fracture

The navicular is a small, boat-shaped bone nestled at the top of the midfoot, bridging the hindfoot and forefoot and playing a central role in the transmission of weight-bearing forces during gait. Despite its modest size, the navicular is particularly vulnerable to stress injury, and a navicular stress fracture is widely regarded as one of the most challenging and consequential injuries in sports medicine. Left undertreated or mismanaged, it can result in delayed union, avascular necrosis, or complete fracture displacement — outcomes that may permanently derail an athlete’s career. Understanding the principles behind its treatment is therefore essential for clinicians, athletes, and allied health practitioners alike.

Why the Navicular Is Vulnerable

The navicular’s susceptibility to stress fracture stems from its precarious blood supply and biomechanical loading environment. The central third of the bone receives relatively poor vascularisation, creating a watershed zone that is slow to heal once injured. During high-impact activities — sprinting, jumping, cutting — repetitive compressive and shear forces concentrate in this region, gradually fatiguing the bone’s microarchitecture before any macroscopic crack becomes visible on plain X-ray. This is why navicular stress fractures are notorious for being missed in the early stages, often misdiagnosed as midfoot sprains or non-specific dorsal foot pain. Delayed diagnosis is itself a major risk factor for poor outcomes, underscoring the need for prompt imaging when a stress fracture is suspected.

Diagnosis and Imaging

Plain radiographs are notoriously insensitive for navicular stress fractures, detecting fewer than half of confirmed cases. When clinical suspicion exists — typically in a track athlete or footballer presenting with dorsal midfoot pain, tenderness on direct palpation of the “N-spot,” and pain provoked by single-leg hopping — advanced imaging is mandatory. CT scanning is the gold standard for characterising fracture type, extent, and displacement, and is used to guide treatment decisions. MRI is highly sensitive for detecting bone marrow oedema in early cases and is particularly useful when the CT appears normal but symptoms persist. Fractures are commonly classified using the Torg system into three grades: incomplete cortical break (Type I), complete fracture without displacement (Type II), and complete fracture with displacement or comminution (Type III).

Non-Operative Management

For Type I and uncomplicated Type II fractures, non-operative management remains a well-supported first-line approach, provided strict adherence to the protocol is observed. The cornerstone of conservative treatment is non-weight-bearing immobilisation in a below-knee cast for a minimum of six weeks. The emphasis on non-weight-bearing is critical — partial weight-bearing has been associated with significantly higher rates of delayed union and re-fracture. During this period, the athlete typically uses crutches and is prohibited from any impact loading of the affected limb.

Following the immobilisation phase, healing is confirmed with repeat CT imaging rather than relying on symptom resolution alone, as clinical improvement often precedes radiological union. Once healing is confirmed, a graded return to weight-bearing is initiated, typically over a further four to six weeks. Running and sport-specific activities are reintroduced progressively under clinical supervision, with a full return to competition generally expected between four and six months from the onset of treatment. Functional rehabilitation during this phase focuses on restoring proprioception, calf strength, and dynamic foot stability — all factors that reduce recurrence risk.

Operative Management

Surgical intervention is indicated for Type III fractures, fractures that have failed conservative management (defined as persistent non-union or re-fracture), and increasingly in elite athletes where a faster, more reliable return to sport is prioritised. The standard surgical technique involves internal fixation using one or two cannulated compression screws inserted along the long axis of the navicular, compressing the fracture site and providing mechanical stability. In cases with established non-union, bone grafting — either autograft from the iliac crest or synthetic alternatives — may be incorporated to stimulate biological healing at the sclerotic fracture margins.

Post-operative management mirrors the conservative protocol in many respects: non-weight-bearing immobilisation for six weeks, followed by progressive rehabilitation once CT-confirmed union is achieved. However, surgical fixation provides the mechanical advantage of compressing the fracture site throughout healing, potentially reducing the risk of re-displacement and offering a more predictable timeline. Studies comparing operative and non-operative outcomes in elite athletes have generally favoured surgery for time to return to sport, with surgical cohorts demonstrating higher rates of complete union and lower recurrence compared to conservative management — though the body of evidence remains relatively modest given the fracture’s overall rarity.

Rehabilitation and Return to Sport

Regardless of whether management is operative or conservative, rehabilitation is a phased, progressive process that must not be rushed. After confirmed radiological union, athletes begin pool running and cycling to maintain cardiovascular fitness before any land-based impact loading is introduced. Straight-line jogging precedes change-of-direction work, and sport-specific drills are added only once the athlete can tolerate sustained running without pain. Throughout this process, load monitoring and athlete education are paramount — navicular stress fractures carry a meaningful recurrence risk, particularly in athletes who return to full training prematurely or in whom the underlying biomechanical or nutritional contributing factors have not been addressed.

Addressing Underlying Risk Factors

Effective long-term management extends beyond the fracture itself. Contributing factors such as low bone density, relative energy deficiency in sport (RED-S), training load errors, and biomechanical abnormalities — including forefoot varus, reduced ankle dorsiflexion, and overpronation — must be identified and corrected. Nutritional assessment, particularly for calcium, vitamin D, and overall energy availability, is an important adjunct to physical treatment. Footwear and orthotic modification may reduce repetitive stress concentration in susceptible individuals.

Navicular stress fractures demand respect. Their insidious onset, diagnostic difficulty, and potential for serious complications make them one of the more exacting injuries encountered in sports medicine. The foundation of successful treatment — whether operative or conservative — is strict non-weight-bearing immobilisation, confirmed radiological healing before load reintroduction, and a patient, structured return-to-sport progression. For the athlete, the prognosis with appropriate management is generally favourable; for those whose treatment is delayed or inadequate, the consequences can be career-defining. Vigilance in diagnosis and discipline in rehabilitation remain the clinician’s most powerful tools.

The Navicular Drop Test: An Assessment Tool for Foot Pronation

The foot is one of the most mechanically complex structures in the human body, comprising 26 bones, 33 joints, and over 100 muscles, tendons, and ligaments working in concert to support posture, absorb shock, and propel movement. Among the many clinical tools used to assess foot mechanics, the navicular drop test stands out for its simplicity, low cost, and diagnostic relevance. First described by Brody in 1982, the navicular drop test has since become a widely used clinical measure of foot pronation, helping practitioners identify biomechanical abnormalities that may contribute to a range of musculoskeletal injuries.

Anatomy and Background

The navicular bone sits on the medial aspect of the midfoot, acting as a keystone of the medial longitudinal arch. It articulates with the talus posteriorly and the three cuneiform bones anteriorly, making it a critical load-transfer point. When the foot pronates — that is, when the arch flattens and the foot rolls inward — the navicular descends toward the ground. Conversely, when the foot supinates or the arch rises, the navicular elevates. This vertical displacement of the navicular serves as a reliable proxy for the degree of pronation occurring across the subtalar and midtarsal joints.

Excessive pronation is a well-documented risk factor for numerous lower limb conditions, including plantar fasciitis, tibialis posterior tendon dysfunction, patellofemoral pain syndrome, medial tibial stress syndrome (shin splints), and iliotibial band syndrome. Because the navicular bone is palpable and its position can be measured with simple tools, the navicular drop test offers clinicians a practical and repeatable means of quantifying arch deformation under load.

Procedure

The navicular drop test is performed in two stages: measurement in a subtalar neutral position and then in a relaxed bilateral standing position.

In the first stage, the patient sits with their foot resting passively on the floor, with the knee flexed to approximately 90 degrees. The clinician palpates the head of the talus on the medial aspect of the foot to find the subtalar neutral position — the point at which the talus is neither pronated nor supinated, identified when the talar head is equally palpable on both its medial and lateral aspects. Once this neutral position is established, the clinician marks the most inferior aspect of the navicular tuberosity with a pen or marking device, and measures its height from the floor using a ruler or index card. This constitutes the “sitting” or non-weight-bearing navicular height.

In the second stage, the patient stands bilaterally with their weight evenly distributed. The foot naturally relaxes into its functional pronated position under the influence of body weight and gravity. The clinician again measures the height of the navicular tuberosity from the floor in this standing position.

The navicular drop value is calculated as the difference between the sitting (neutral) navicular height and the standing (relaxed) navicular height. This number, expressed in millimetres, reflects how far the navicular descends when the foot moves from a non-weight-bearing neutral alignment to a loaded, functional position.

Interpretation

A navicular drop of less than 10 mm is generally considered within normal range, though some authors use a threshold of 5 to 9 mm as the accepted reference range for typical foot mechanics. A drop of 10 mm or greater is widely cited as indicative of excessive pronation, sometimes referred to as a hyperpronated or flatfoot posture. Values of 15 mm or more suggest significantly altered arch mechanics and may warrant further investigation or intervention.

However, it is important to note that normal values can vary based on age, sex, body mass index, and activity level. Athletes, particularly runners, may present with slightly higher navicular drop values without experiencing any pathology. Clinical interpretation should therefore always consider the broader context of the patient’s history, symptoms, and physical findings.

Reliability and Validity

The navicular drop test has been the subject of considerable research examining its psychometric properties. Intra-rater reliability — the consistency of measurements taken by the same clinician on the same patient — is generally reported as good to excellent, with intraclass correlation coefficients (ICCs) typically ranging from 0.78 to 0.95 in various studies. Inter-rater reliability, or consistency between different clinicians, is somewhat more variable, with ICCs ranging from moderate to good. This variability is largely attributed to differences in identifying the subtalar neutral position, which requires clinical skill and experience to determine accurately.

In terms of validity, several studies have found that the navicular drop test correlates meaningfully with more sophisticated three-dimensional gait analysis measurements of rearfoot eversion and arch deformation. It has also demonstrated associations with injury risk in athletic populations. A prospective study in military recruits found that higher navicular drop values were associated with increased rates of overuse injuries during training, lending support to the test’s clinical relevance.

Limitations

Despite its utility, the navicular drop test has several important limitations. First, the process of finding subtalar neutral position introduces a degree of subjectivity and requires training to perform consistently. Second, the test measures static arch deformation rather than dynamic foot function during walking or running, which limits its ability to capture the full complexity of foot mechanics in motion. Third, it assesses only the medial longitudinal arch and does not account for transverse arch behaviour or forefoot mechanics.

Furthermore, the test does not distinguish between the contributions of different anatomical structures to arch collapse — whether the deficit lies in passive ligamentous support, active muscular control (particularly tibialis posterior), or bony morphology. This distinction may be important for guiding treatment.

Clinical Applications

Despite these limitations, the navicular drop test remains a valuable part of the clinical assessment toolkit. It is routinely used in sports medicine, podiatry, physiotherapy, and orthopaedic settings to screen for excessive pronation, guide orthotic prescription, monitor treatment response, and contribute to injury risk stratification. Its simplicity, low cost, and reasonable reliability make it accessible in virtually any clinical environment without the need for expensive motion capture technology.

The navicular drop test represents an elegant solution to a clinical challenge: how to quantify a complex, three-dimensional biomechanical event using simple, low-tech means. While it is not without limitations, its combination of accessibility, reasonable reliability, and clinical meaningfulness has secured its place in the assessment of foot and lower limb mechanics. Used thoughtfully alongside other clinical findings, it remains an important tool in the understanding and management of foot-related pathology.

The Treatment of Midfoot Osteoarthritis

Midfoot osteoarthritis is a degenerative joint condition affecting the complex articulations of the midfoot, most commonly involving the tarsometatarsal (Lisfranc) joints, the naviculocuneiform joints, and the calcaneocuboid joint. Though less frequently discussed than osteoarthritis of the hip or knee, midfoot osteoarthritis can be profoundly disabling, impairing a patient’s ability to walk, stand, and perform daily activities. Its aetiology is varied — it may arise following trauma such as Lisfranc injuries, develop secondary to inflammatory arthritis, or occur as a primary degenerative process. Management requires a thorough understanding of the anatomy, biomechanics, and the spectrum of treatments available, ranging from conservative measures to surgical reconstruction.

Understanding the Pathology and Presentation

The midfoot functions as a rigid lever during the push-off phase of gait, and any disruption to the integrity of its joints results in pain, deformity, and altered mechanics. Patients with midfoot osteoarthritis typically present with dorsal midfoot pain, localised tenderness over affected joints, stiffness — particularly in the morning or after periods of rest — and swelling. Over time, osteophyte formation on the dorsum of the foot becomes prominent and may cause secondary problems such as shoe-fitting difficulties and skin irritation. Weight-bearing radiographs are the cornerstone of diagnosis, demonstrating joint space narrowing, subchondral sclerosis, cyst formation, and osteophyte development. In cases where plain films are inconclusive, CT scanning provides superior bony detail, while MRI is useful for assessing early cartilage loss and bone marrow oedema.

Conservative Management

The initial approach to midfoot osteoarthritis is invariably non-operative. The goals of conservative treatment are pain reduction, functional improvement, and slowing disease progression. A structured, stepwise approach is recommended, beginning with the simplest interventions before escalating to more complex modalities.

Footwear modification is fundamental. Stiff-soled shoes with a rocker-bottom profile are particularly effective, as they reduce the bending forces transmitted across the midfoot joints during the toe-off phase of gait. A well-cushioned, supportive shoe with adequate width also minimises pressure on dorsal osteophytes and accommodates any swelling or deformity.

Custom orthotics and foot orthoses complement footwear modification. A rigid or semi-rigid custom insole with a medial arch support reduces motion at the affected joints and redistributes plantar pressures. In more severe cases, a carbon fibre footplate or a full-length stiff insert can provide substantial symptomatic relief by effectively immobilising the midfoot during ambulation.

Analgesic and anti-inflammatory pharmacotherapy plays an adjunctive role. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for pain management, though their use must be balanced against gastrointestinal, renal, and cardiovascular risks, particularly in older patients. Topical NSAIDs offer a safer alternative with more localised effect. Paracetamol remains a useful baseline analgesic, and short courses of oral corticosteroids may be considered in inflammatory flares.

Intra-articular corticosteroid injections, typically guided by ultrasound or fluoroscopy to ensure accurate placement, provide targeted relief and can serve both therapeutic and diagnostic purposes. The response to injection is variable; some patients experience substantial improvement lasting weeks to months, while others derive minimal benefit. Viscosupplementation with hyaluronic acid has also been trialled in small cohorts, with some evidence of modest benefit, though its role remains less established than in knee osteoarthritis.

Physiotherapy is an important adjunct, focusing on lower limb strengthening, gait retraining, and proprioceptive exercises. Strengthening the intrinsic foot muscles and the tibialis posterior can improve dynamic arch support and offload arthritic joints. Activity modification — avoiding high-impact activities and prolonged standing — is encouraged alongside weight management, given that obesity significantly increases forces across the midfoot.

Interventional and Surgical Management

When conservative measures fail to provide adequate relief, typically after six to twelve months of optimised non-operative care, surgical intervention is considered. The decision to operate depends on the severity of symptoms, the degree of radiographic involvement, the patient’s functional demands, and the presence of deformity.

For isolated, refractory pain without significant malalignment, minimally invasive or arthroscopic debridement and osteophyte excision (cheilectomy) may offer symptomatic benefit. This is particularly relevant where prominent dorsal osteophytes cause pain or shoe irritation without advanced joint destruction. However, these procedures address symptoms rather than the underlying arthritis and are not suitable in cases of severe joint space loss.

Arthrodesis — surgical fusion of the affected joints — remains the gold standard operative treatment for advanced midfoot osteoarthritis. The aim of fusion is to eliminate pain by abolishing motion at the diseased joints while achieving a plantigrade, functional foot position. The most commonly fused joints include the medial, intermediate, and lateral tarsometatarsal joints, as well as the naviculocuneiform joints where involved. Fusion is typically achieved using a combination of internal fixation — plates, screws, or staples — with autologous bone graft to promote union.

Outcomes following midfoot arthrodesis are generally favourable, with the majority of patients reporting significant pain relief and improved function. Union rates in modern series exceed 90% when meticulous surgical technique is employed. Nonetheless, surgery carries risks including non-union, malunion, wound complications, neurovascular injury, and hardware irritation requiring removal. The development of adjacent joint arthritis following fusion is a recognised long-term concern, as altered biomechanics may accelerate degeneration in surrounding joints.

Total joint replacement of the midfoot has not gained widespread adoption due to the complex anatomy, high mechanical demands, and the limited evidence base supporting implant longevity in this region. Research into midfoot arthroplasty continues, but fusion remains the preferred surgical solution.

Midfoot osteoarthritis is a challenging condition with significant impact on quality of life. Treatment follows a logical progression from conservative measures — footwear modification, orthotics, analgesia, injections, and physiotherapy — to surgical arthrodesis in refractory cases. Accurate diagnosis, patient-specific goal-setting, and a multidisciplinary approach involving orthopaedic or podiatric surgeons, physiotherapists, and allied health professionals are essential to achieving optimal outcomes. As research advances, refinements in surgical technique and the development of new biological therapies may further improve the management of this disabling condition.

How Menopause Can Affect the Feet

Menopause is one of the most significant physiological transitions in a woman’s life, marking the end of reproductive function and bringing with it a cascade of hormonal changes that ripple through virtually every system in the body. While much attention is rightly given to symptoms such as hot flushes, mood changes, and bone density loss, one area that is frequently overlooked is the feet. The feet are complex structures — each one containing 26 bones, 33 joints, and more than 100 muscles, tendons, and ligaments — and they are surprisingly vulnerable to the hormonal shifts that accompany menopause. Understanding how these changes manifest in the feet can help women seek appropriate care and maintain their mobility and quality of life during this transition.

The Role of Oestrogen

At the heart of menopause’s impact on the feet is the dramatic decline in oestrogen. This hormone does far more than regulate the menstrual cycle; it plays a critical role in maintaining the integrity of connective tissue, bone density, joint lubrication, and skin health throughout the body. When oestrogen levels fall sharply during perimenopause and menopause, tissues that depended on it for structure and elasticity begin to change. The feet, which bear the full weight of the body with every step, are particularly susceptible to these changes.

Ligament Laxity and Arch Changes

One of the most structurally significant effects of falling oestrogen is increased ligament laxity. Oestrogen helps maintain the tension and resilience of ligaments, and as levels drop, these connective tissues can become looser and less supportive. In the feet, this often results in a gradual flattening of the arches — a condition known as fallen arches or adult-acquired flat foot. Women may notice that their feet appear wider or longer than they used to be, or that shoes that once fitted comfortably are now too narrow or too short. This is not merely an inconvenience; arch collapse can alter the biomechanics of the entire lower body, leading to pain in the feet, ankles, knees, hips, and lower back if left unaddressed.

Plantar Fasciitis and Heel Pain

The plantar fascia is a thick band of tissue running along the sole of the foot from the heel to the toes. It supports the arch and absorbs the shock of walking. With increased ligament laxity, added body weight — which is common during menopause due to metabolic changes — and reduced tissue resilience, the plantar fascia can become strained and inflamed. Plantar fasciitis, which causes sharp, stabbing heel pain particularly in the morning or after periods of rest, is significantly more common in menopausal and post-menopausal women. The condition can become chronic if not treated, making everyday activities like walking and standing deeply uncomfortable.

Bone Density and Stress Fractures

Oestrogen is a key protector of bone density. As levels decline during menopause, women are at heightened risk of osteoporosis — a condition in which bones become porous and fragile. The feet contain numerous small bones that are subjected to repetitive loading, and as bone density decreases, stress fractures become more likely. These hairline fractures can occur without a specific injury, developing gradually from the cumulative stress of ordinary weight-bearing activity. Pain and swelling in the foot without an obvious cause in a menopausal woman should always raise the possibility of a stress fracture, and prompt evaluation is important to prevent the fracture from worsening.

Joint Pain and Arthritis

Oestrogen has anti-inflammatory properties, and its decline during menopause can contribute to increased joint inflammation throughout the body. The small joints of the feet are common sites for both osteoarthritis and rheumatoid arthritis, and many women notice that joint pain in their feet worsens around the time of menopause. Stiffness, swelling, and aching in the toes and midfoot can make walking painful and reduce overall activity levels. There is also evidence that the onset or acceleration of rheumatoid arthritis — an autoimmune condition — may be influenced by hormonal changes associated with menopause.

Dry Skin, Cracked Heels, and Nail Changes

The skin on the feet undergoes noticeable changes during menopause. Oestrogen helps maintain the skin’s moisture, thickness, and ability to heal. As levels fall, the skin becomes thinner, drier, and less elastic. On the feet, this frequently manifests as dry, flaky skin and severely cracked heels — a condition known as heel fissures. In some cases, these cracks can become deep and painful, creating entry points for infection. Toenails may also become more brittle and prone to splitting or fungal infections, as the reduced circulation and skin changes that accompany menopause create a less hostile environment for organisms like dermatophytes.

Swelling and Poor Circulation

Many menopausal women experience oedema — swelling caused by fluid retention — particularly in the lower legs and feet. Hormonal fluctuations can disrupt the body’s fluid regulation mechanisms, and reduced circulation, which is also associated with menopause, means that fluid pools more easily in the extremities. Hot flushes, which cause sudden dilation of blood vessels, can further exacerbate circulation irregularities. Women may find that their feet are noticeably puffier at the end of the day, making shoes feel tight and walking uncomfortable.

Bunions and Toe Deformities

The ligament laxity and biomechanical changes that occur during menopause can accelerate the development of bunions — bony protrusions at the base of the big toe — as well as hammer toes and other structural deformities. These conditions may have been present in a mild form for years but can worsen significantly as the supportive structures of the foot lose their integrity.

Managing Menopausal Foot Health

Awareness is the first step. Women entering perimenopause should pay close attention to any new foot symptoms and seek professional assessment from a podiatrist. Supportive footwear, custom orthotics, and targeted exercises to strengthen the intrinsic muscles of the foot can help counteract arch collapse and biomechanical changes. Moisturising the feet daily, maintaining a healthy weight, and engaging in low-impact exercise to support bone density and circulation are all beneficial strategies. Hormone replacement therapy (HRT), where appropriate and prescribed by a medical professional, may also help mitigate some of the connective tissue and bone density changes.

Menopause is a whole-body event, and the feet deserve the same attention and care as any other system affected by this transition. By recognising how hormonal change manifests from the ground up, women can take proactive steps to protect their foot health and stay active and comfortable for decades to come.

Treatment of Mueller-Weiss Syndrome

Mueller-Weiss syndrome is a rare and often misdiagnosed condition characterised by spontaneous osteonecrosis of the navicular bone in the adult foot. Unlike Kohler’s disease, which affects children, Mueller-Weiss syndrome typically presents in middle-aged adults, more commonly in women, and is frequently bilateral. First described independently by Mueller in 1927 and Weiss in 1927, the condition involves progressive collapse, fragmentation, and sclerosis of the navicular bone — a small but biomechanically critical bone located at the apex of the medial longitudinal arch. Understanding the treatment of Mueller-Weiss syndrome requires first appreciating the complexity of its pathophysiology, the staging of disease progression, and the significant impact it has on a patient’s daily function and quality of life.

Pathophysiology and Staging

The navicular bone is considered a “watershed” area of the foot, receiving its vascular supply from the ends inward. This makes its central portion vulnerable to ischaemia under conditions of mechanical overload, delayed ossification, or vascular compromise. The precise aetiology of Mueller-Weiss syndrome remains incompletely understood, but biomechanical stress, repetitive microtrauma, and intrinsic vascular insufficiency are considered contributing factors. Over time, the navicular undergoes avascular necrosis, leading to flattening and lateral extrusion of the bone, disruption of the talonavicular joint, and collapse of the medial arch.

Staging systems, most notably that proposed by Maceira and Rochera, classify the condition from Stage I (osteonecrosis without deformity) through to Stage V (severe collapse with peritalar subluxation and significant arthrosis). Treatment is guided primarily by disease stage, symptom severity, and the functional demands of the patient.

Conservative Management

In the early stages of Mueller-Weiss syndrome — particularly Stages I through III — conservative (non-operative) management remains the cornerstone of treatment. The primary goals are pain relief, offloading the navicular, and halting or slowing disease progression.

Activity modification is often the first step. Patients are advised to reduce weight-bearing activities, avoid prolonged standing, and modify footwear. This alone can provide meaningful symptom relief in mild cases.

Orthotic therapy plays a central role in conservative management. Custom-made foot orthoses designed to support the medial longitudinal arch reduce the mechanical load transmitted through the navicular. A well-fitted orthosis can redistribute forces away from the compromised bone, reducing pain and potentially slowing structural deterioration. In more severe cases, a University of California Biomechanics Laboratory (UCBL) orthosis or a rigid arch support may be required.

Immobilisation using a below-knee cast or a removable walking boot is frequently employed, particularly during acute flares or periods of significant pain. Immobilisation for six to twelve weeks may allow inflammation to subside and can be combined with protected weight-bearing or non-weight-bearing periods depending on the severity of symptoms and degree of collapse.

Pharmacological management is generally adjunctive. Non-steroidal anti-inflammatory drugs (NSAIDs) are used for analgesia and reduction of periarticular inflammation. There is limited but emerging evidence supporting the use of bisphosphonates — agents that inhibit osteoclast-mediated bone resorption — in avascular necrosis conditions. While robust trials specific to Mueller-Weiss syndrome are lacking, some clinicians advocate their use in early stages to preserve bone density and reduce the risk of further collapse.

Extracorporeal shockwave therapy (ESWT) has been explored as a non-invasive modality to stimulate bone healing and angiogenesis in avascular necrosis conditions. While evidence remains preliminary in the context of Mueller-Weiss syndrome specifically, its use in adjacent conditions such as plantar fasciitis and other bone stress pathologies provides a rationale for its application.

Surgical Management

When conservative measures fail to provide adequate relief, or when the disease has progressed to advanced stages (Stages III–V) with significant structural deformity and arthrosis, surgical intervention is considered.

Joint-sparing procedures are preferred in earlier surgical stages. Drilling or core decompression of the navicular aims to reduce intraosseous pressure and stimulate revascularisation. Bone grafting — either autologous or synthetic — may be used to reconstruct the collapsed navicular and restore arch height. These procedures are most appropriate when joint surfaces remain relatively preserved and the deformity is correctable.

Osteotomies to realign the foot and offload the navicular may be combined with navicular reconstruction in select cases. A medialising calcaneal osteotomy, for example, can shift weight-bearing forces to reduce stress on the medial column, complementing navicular reconstruction efforts.

Arthrodesis (fusion) becomes necessary in advanced disease where articular cartilage destruction and peritalar subluxation are established. The most commonly performed fusion in Mueller-Weiss syndrome is talonavicular arthrodesis, which eliminates painful motion at the affected joint and provides durable pain relief. In cases where adjacent joints are also involved — particularly the naviculocuneiform joint — a double or triple arthrodesis (incorporating the subtalar and calcaneocuboid joints) may be necessary to achieve a stable, plantigrade foot.

Triple arthrodesis, while a significant surgical intervention, has demonstrated reliable outcomes in end-stage Mueller-Weiss syndrome. It eliminates motion across the hindfoot and midfoot, corrects deformity, and substantially reduces pain. The trade-off is loss of foot flexibility, which must be carefully discussed with patients preoperatively.

Total navicular replacement with a custom or standard prosthetic implant represents an emerging alternative in cases where joint-sparing reconstruction is inadequate but the surgeon wishes to avoid fusion. Experience with this technique remains limited, and long-term outcomes are not yet well established.

Rehabilitation and Outcomes

Regardless of whether treatment is conservative or surgical, rehabilitation is an essential component of care. A structured physiotherapy programme addressing foot and ankle strengthening, proprioception, and gait retraining helps restore function and prevent compensatory injuries. Following arthrodesis, patients typically require six to twelve weeks of immobilisation followed by a graduated return to weight-bearing.

Outcomes in Mueller-Weiss syndrome are variable and depend heavily on the stage at diagnosis and the timeliness of intervention. Early-stage disease managed conservatively often achieves satisfactory pain control, though ongoing orthotic use may be required indefinitely. Surgical outcomes, particularly following arthrodesis, are generally favourable for pain relief, though functional limitations may persist.

Mueller-Weiss syndrome poses a significant diagnostic and therapeutic challenge due to its rarity and progressive nature. A staged, individualised approach to treatment — progressing from conservative offloading and orthotic support to surgical reconstruction or arthrodesis as required — offers the best prospect of maintaining function and quality of life. Heightened clinical awareness and early diagnosis remain critical, as intervention at earlier disease stages affords the greatest opportunity for joint preservation and symptom control.

How to Deal with a Morton’s Neuroma in the Foot

Morton’s neuroma is one of those conditions that sneaks up on you. One day you notice a mild burning sensation in the ball of your foot, and before long it feels as though you are walking on a pebble that simply will not move. Named after the American surgeon Thomas George Morton, who first described the condition in the 1870s, Morton’s neuroma is not actually a tumour. It is a thickening of the tissue surrounding one of the nerves leading to your toes — most commonly between the third and fourth toes — triggered by irritation, compression, or injury to that nerve.

Understanding how to manage this condition well can mean the difference between months of worsening pain and a swift return to comfortable, active life.

Recognising the Symptoms

Before you can treat Morton’s neuroma, you need to identify it. The hallmark symptoms include a burning or sharp pain in the ball of the foot, tingling or numbness in the toes, and that distinctive sensation of standing on a small stone or a bunched-up sock. Symptoms are often worst when wearing tight or narrow shoes and typically improve when you remove your footwear and massage the area. Some people describe a clicking feeling when they walk, which occurs as the thickened nerve tissue moves between the metatarsal bones.

If you experience these symptoms persistently — especially if they begin interrupting daily activities or waking you at night — it is worth seeing a doctor or podiatrist. A clinical examination, sometimes combined with an ultrasound or MRI, can confirm the diagnosis and rule out other causes such as stress fractures or bursitis.

Conservative Management First

The vast majority of Morton’s neuroma cases respond well to conservative treatment. Surgery is rarely the first port of call, and most people achieve significant relief without it.

Footwear changes are the single most impactful first step. Tight, narrow, or high-heeled shoes compress the forefoot, squeezing the metatarsal bones together and aggravating the nerve. Switching to shoes with a wide toe box gives the bones room to spread and reduces pressure on the neuroma. Shoes should have low heels — ideally less than 2.5 cm — and adequate cushioning underfoot. This one change alone can produce dramatic improvement within a few weeks.

Metatarsal pads are small, dome-shaped inserts placed just behind the ball of the foot, usually under the second and third metatarsal heads. Their purpose is to splay the metatarsal bones slightly apart, relieving pressure on the trapped nerve. These pads are inexpensive, available from pharmacies, and can be fitted into most shoes. A podiatrist can advise on correct placement, as positioning is everything — a badly placed pad can make things worse.

Custom orthotics take this a step further. A podiatrist can prescribe a moulded insole that addresses your specific foot mechanics. If overpronation (the inward rolling of the foot during walking) is contributing to nerve compression, a corrective orthotic may reduce the forces that worsen the neuroma over time.

Activity modification is also important. High-impact activities such as running on hard surfaces can flare symptoms considerably. During an acute phase, switching to lower-impact exercise — swimming, cycling, or walking on softer terrain — allows inflammation to settle without forcing you into complete inactivity.

Ice and anti-inflammatory medication can help manage pain and swelling during a flare-up. Applying an ice pack wrapped in a cloth for 15 to 20 minutes several times a day, and taking over-the-counter anti-inflammatories such as ibuprofen (if you have no contraindications), can provide meaningful short-term relief.

When Conservative Measures Are Not Enough

If footwear adjustments, pads, and activity changes have not delivered sufficient improvement after several weeks, the next step is usually a corticosteroid injection. Administered by a doctor or podiatrist — often with ultrasound guidance for precision — a steroid injection delivers a powerful anti-inflammatory directly to the site of the neuroma. Many patients experience substantial relief after one or two injections, and the effect can last for months. Repeated injections are possible but are generally limited due to the risk of soft tissue damage over time.

Sclerosing alcohol injections are another non-surgical option offered by some specialists. A series of injections using dilute alcohol are administered to gradually shrink the neuroma by damaging the nerve tissue responsible for pain signals. Research suggests this approach can be effective for many patients, though it typically requires multiple treatment sessions over several weeks.

Radiofrequency ablation, a procedure using targeted heat to disrupt pain signals from the nerve, is also available in some clinics and has shown promising results for patients who have not responded to other treatments.

Surgical Options

Surgery is considered when conservative and minimally invasive treatments have failed after at least six months of consistent effort. The two main surgical approaches are neurectomy — the removal of the affected nerve — and nerve decompression, which involves releasing the tight ligament pressing on the nerve without removing it.

Neurectomy has a high success rate for pain relief, but because the nerve is removed, permanent numbness in the adjacent toes is expected. For most patients this is a small price to pay for freedom from chronic pain, but it is worth discussing thoroughly with your surgeon beforehand. Recovery typically involves several weeks of limited weight-bearing, followed by a gradual return to normal footwear.

Nerve decompression preserves the nerve and carries a lower risk of permanent numbness, though it may have a slightly lower success rate for complete pain relief.

Prevention and Long-Term Care

Once you have managed a Morton’s neuroma, sensible footwear habits become a long-term commitment. Continuing to wear well-fitted, wide-toed shoes — especially during high-activity periods — is the most reliable way to prevent recurrence. Maintaining a healthy weight reduces overall load through the forefoot. Strengthening the intrinsic muscles of the foot through exercises prescribed by a physiotherapist can also improve foot mechanics and reduce susceptibility to nerve compression.

Morton’s neuroma can be a frustrating condition, but with the right approach it is very manageable. Starting with the simplest interventions and escalating only if necessary gives most people an excellent chance of returning to full, comfortable function.

Mizuno Running Shoes: Engineering Excellence from Japan

A Legacy Built on Craftsmanship

When runners debate the finest footwear in the world, names like Nike and Adidas inevitably dominate the conversation. Yet for those who have laced up a pair of Mizuno running shoes, there is often a quiet, knowing confidence — a sense that they have discovered something the mainstream market has not quite caught up with. Founded in Osaka, Japan in 1906 by brothers Rihachi and Ridzo Mizuno, the Mizuno Corporation has spent more than a century refining the art and science of athletic performance. Their running shoes, in particular, stand as a testament to the Japanese philosophy of monozukuri — the art of making things with care, precision, and deep respect for the craft.

Mizuno entered the running shoe market in earnest during the 1970s, a period when the global running boom was just beginning to take shape. While competitors rushed product to market to meet surging demand, Mizuno took a more methodical approach, investing heavily in biomechanics research and materials science. That foundational commitment to engineering over marketing has defined the brand ever since. Today, Mizuno operates one of the most sophisticated footwear development labs in the industry, and its running shoes are worn by elite athletes and weekend warriors across six continents.

The Science Behind the Stride

What separates Mizuno running shoes from the competition begins at the molecular level. The company’s signature midsole technology, known as Wave Plate, is among the most distinctive innovations in running footwear history. Unlike conventional foam-based cushioning systems, the Wave Plate is a hard, fan-shaped insert embedded within the midsole that simultaneously provides cushioning and stability. When the foot strikes the ground, the Wave Plate disperses energy horizontally rather than allowing it to compress vertically — a mechanism Mizuno describes as “spreading the force.” The result is a remarkably smooth, consistent ride that reduces the peak impact on joints over the course of a long run.

The Wave Plate system debuted in 1997 and has since been refined across dozens of shoe models. Different configurations of the plate serve different purposes: a flat wave suits neutral runners seeking cushioning, while a parallel wave offers greater motion control for overpronators. This level of biomechanical nuance is rarely found in mainstream running shoe design, and it reflects Mizuno’s belief that a shoe should be engineered around the specific demands of the runner’s gait, not simply styled to look fast.

Beyond the Wave Plate, Mizuno uses a proprietary foam compound called AP+ (Articulated Propulsion+) in several of its performance models. This material offers a high energy return rate, meaning that the shoe stores energy during ground contact and releases it at toe-off, propelling the runner forward with each step. In long-distance racing and training, this efficiency can translate into meaningful time savings and reduced muscular fatigue.

Flagship Models and Their Devotees

Among Mizuno’s extensive lineup, a handful of models have earned near-legendary status. The Wave Rider is perhaps the brand’s most beloved shoe, a versatile everyday trainer that has been in continuous production since 1997. Renowned for its balanced blend of cushioning, responsiveness, and durability, the Wave Rider has accumulated a fiercely loyal following. Many runners report wearing the same model through dozens of iterations, trusting that Mizuno’s incremental updates will improve the shoe without abandoning the qualities that made them fall in love with it in the first place.

The Wave Inspire serves a similar role for runners who need additional stability. Built around a firmer medial post and a dual-density foam system, it gently corrects mild to moderate overpronation without the rigid, corrective feel of traditional motion control shoes. For runners who spent years in clunky stability footwear before discovering Mizuno, the Wave Inspire can feel like a revelation.

At the performance end of the spectrum sits the Wave Rebellion Pro, Mizuno’s answer to the carbon-plated racing shoe revolution. Featuring a full-length carbon fiber plate embedded in an energy-return foam stack, it delivers the propulsive efficiency demanded by competitive runners while maintaining the brand’s characteristic smoothness underfoot. Elite marathoners have used the Wave Rebellion Pro to set personal records on courses worldwide, proving that Mizuno’s engineering pedigree extends all the way to the podium.

Durability and Value

One of the most frequently cited advantages of Mizuno running shoes is their durability. Where some popular competitors build shoes designed to last 300 to 400 miles before meaningful breakdown occurs, Mizuno’s upper materials and outsole rubber are engineered for longevity. Runners commonly report getting 500 miles or more out of a pair of Wave Riders before noticing a decline in performance. For high-mileage athletes, this translates into a lower cost-per-mile than shoes with a more aggressive initial price tag might suggest.

The outsole rubber compound, which Mizuno sources from carefully selected suppliers, is formulated to resist abrasion on both road and track surfaces. The upper fabrics, meanwhile, are stitched and bonded with exceptional precision — a quality that is immediately apparent when handling a Mizuno shoe and examining the seam work and overlay placement. These are not shoes built to photograph well in a flat lay; they are built to perform mile after mile, in all conditions.

A Brand for Those Who Know

Mizuno occupies a curious position in the running shoe market. It is not a niche brand — it sells millions of pairs annually and sponsors major international athletics — yet it has never quite broken through to the same cultural ubiquity as its American and German rivals. This is partly by design. Mizuno has historically invested more in product development than in celebrity endorsements or lifestyle marketing, trusting that the shoes would speak for themselves through word-of-mouth among serious runners.

That approach has created a passionate, knowledgeable consumer base. Ask a dedicated runner why they wear Mizuno and they are unlikely to mention an influencer or a television advertisement. They will tell you about the feel of the Wave Plate on a long Sunday run, or the way the Wave Rider fits their foot like a second skin after years of loyalty to the model. This is a brand that earns its following one runner at a time, through performance rather than persuasion.

In a market saturated with bold claims and breathless innovation cycles, Mizuno’s quiet confidence stands apart. For runners who have discovered what the brand offers, there is rarely any reason to look elsewhere.

Barefoot and Beyond: The Case for Minimalist Running Shoes

There is a particular kind of runner who, somewhere between mile eight and mile twelve, begins to wonder whether the thick foam platform beneath their feet is helping them or quietly betraying them. This runner — increasingly common, increasingly curious — has probably stumbled into the world of minimalist running shoes, a category that promises not innovation but subtraction: less cushioning, less structure, less intervention between the human foot and the earth beneath it. It is a philosophy disguised as footwear, and its implications reach far beyond athletic performance.

Minimalist running shoes are defined by what they lack. Compared to conventional trainers, they feature dramatically reduced heel-to-toe drop (often zero millimetres, against the 10–12mm of a standard shoe), thinner and more flexible soles, wider toe boxes, and significantly less cushioning overall. The goal is to allow the foot to move as naturally as possible — to flex, splay, and feel the ground — while still offering some protection from sharp objects and abrasion. At their most extreme, they approach barefoot sandals. At their most moderate, they remain surprisingly lightweight shoes that simply get out of the foot’s way.

The philosophical roots of minimalist running stretch back to 2009, when Christopher McDougall published Born to Run, a book about the Tarahumara people of Mexico’s Copper Canyon, who run extraordinary distances in little more than thin leather sandals. The book became a cultural phenomenon, igniting both a minimalist shoe movement and a years-long debate among biomechanists, podiatrists, coaches, and athletes about how humans were “meant” to run. The evolutionary argument at the heart of minimalism holds that the human foot — with its 26 bones, 33 joints, and over 100 muscles, tendons, and ligaments — is already a masterpiece of engineering, and that centuries of shoe-wearing, culminating in the heavily padded running shoe of the modern era, have atrophied this extraordinary structure rather than supported it.

The biomechanical case for minimalism centres on foot strike. Runners in thick-heeled shoes tend to land on their heels — a pattern that sends a sharp impact force up through the ankle, knee, and hip with each stride. Minimalist runners, by contrast, are encouraged (sometimes forced) to land on the midfoot or forefoot, which allows the arch and the calf musculature to absorb impact gradually, the way a spring would. Proponents argue this not only reduces injury risk but produces a more efficient stride, since energy stored in the tendons of the foot and Achilles is partially returned with each step.

The research, however, tells a more nuanced story. Some studies have found that transitioning to minimalist footwear reduces knee loading and improves foot strength significantly — one frequently cited paper found that six months of minimalist shoe use increased intrinsic foot muscle volume noticeably. But other studies have documented elevated rates of stress fractures and metatarsal injuries in runners who transitioned too quickly, their feet unprepared for the sudden increase in mechanical demand. The evidence, taken together, suggests that minimalist shoes are neither magic nor dangerous — they are tools, and like most tools, their value depends entirely on how they are used.

This brings us to the most important and most overlooked dimension of the minimalist debate: transition. The foot, accustomed to years of passive support, cannot simply be thrown into a zero-drop, paper-thin shoe and asked to perform. The intrinsic muscles of the foot — the flexor digitorum brevis, the abductor hallucis, the plantar fascia — must be progressively conditioned over months, not weeks. Runners who have successfully made the switch almost universally describe the same process: beginning with short distances, running on varied terrain, incorporating foot-strengthening exercises, and listening carefully to the signals their body produces. Those who rush this process tend to regret it. Those who commit to the gradual approach often report transformative results.

Beyond injury and performance, minimalist shoes carry an appeal that is harder to quantify but just as real: the sensory experience. Running in a thin-soled shoe on a forest path, a sandy beach, or even a quiet street produces a kind of feedback that heavily cushioned shoes deliberately suppress. You feel the texture of the ground, the slight irregularity of a root, the give of moss. This proprioceptive richness — the body’s awareness of its own position in space — is not merely pleasant; it is functionally important. Better ground feel tends to produce more careful, adaptive foot placement, which may explain why many trail runners have gravitated toward moderately minimalist shoes even without subscribing to any particular ideological position on the matter.

The market reflects this growing complexity. Where once the choice was broadly between maximal cushioning and barefoot-style shoes, there is now a genuine spectrum. Companies like Vivobarefoot, Xero Shoes, and Merrell produce shoes at the radical end, with negligible drop and minimal padding. Brooks, Saucony, and Asics offer moderately low-drop options for runners who want some of the benefits without full commitment. Even the maximalist end of the market — led by brands like Hoka — has produced runners curious about what lies at the other extreme, creating a generation of experimenters willing to maintain multiple shoes for different training purposes.

What minimalism ultimately offers, at its best, is not a single answer but a valuable question: how much does my shoe need to do, and how much should I be doing myself? It is a question with different answers for different runners — different body types, different histories, different goals, different terrain. But asking it at all tends to produce more thoughtful, more embodied runners, people who have considered the relationship between their foot and the ground they cover, and made a conscious choice about how to mediate it.

The foot has been running for roughly two million years. The modern cushioned running shoe has existed for roughly fifty. Minimalism does not argue that we should ignore everything learned in those fifty years. It argues, more modestly, that we should not forget the two million.

Metatarsus Adductus: Understanding a Common Foot Deformity

Metatarsus adductus (MA) is one of the most frequently encountered congenital foot deformities in paediatric medicine, characterised by an inward curvature of the forefoot relative to the hindfoot. Sometimes described colloquially as “in-toeing,” the condition affects the metatarsal bones — the five long bones of the midfoot — which deviate medially, giving the foot a distinctly curved or kidney-bean shape when viewed from below. Though often alarming to new parents who notice the unusual appearance of their infant’s feet, metatarsus adductus is in the vast majority of cases a benign and self-resolving condition. Nevertheless, a clear understanding of its aetiology, diagnosis, and management remains essential for clinicians, parents, and allied health professionals alike.

Aetiology and Epidemiology

Metatarsus adductus occurs in approximately one to two per thousand live births, making it among the most common musculoskeletal anomalies seen in neonates. Its cause is generally attributed to intrauterine positional factors — specifically, the position of the foetus within the uterus during the final weeks of pregnancy. When the foot is persistently compressed or held in an adducted position against the uterine wall or the other limb, the soft tissues and developing bones may adapt accordingly. This theory is supported by the higher prevalence of MA in firstborn children (where the uterus is typically less distensible), in multiple pregnancies, and in cases of oligohydramnios, all of which reduce available intrauterine space.

There is also evidence of a genetic predisposition. Studies have reported familial clustering, with a higher incidence among siblings and first-degree relatives of affected individuals. Additionally, metatarsus adductus is more commonly observed in females than males, though the reason for this sex-based difference is not fully understood. The condition is bilateral in approximately 50% of cases, further suggesting a systemic developmental influence rather than purely mechanical compression.

Clinical Presentation and Classification

The hallmark of metatarsus adductus is a forefoot that curves inward while the hindfoot and ankle appear normal or near-normal. On clinical examination, the lateral border of the foot — which should be straight — is visibly convex, and a deep crease may be present along the medial arch. The heel is typically in a neutral or slightly valgus position, which distinguishes MA from clubfoot (talipes equinovarus), a more severe and structurally complex deformity that also involves the hindfoot and ankle.

Clinicians commonly use the Bleck classification system to grade the severity of MA based on the flexibility of the foot. In mild cases, the foot can be passively corrected beyond the neutral position with gentle pressure — these cases almost universally resolve without intervention. In moderate cases, the foot corrects only to a neutral position with manipulation. Severe cases are those in which the foot cannot be passively corrected to neutral, and these are the cases most likely to require active treatment. A simple assessment tool is the heel bisector line: a line drawn through the midpoint of the heel should normally pass through the second or third toe; in MA, this line falls lateral to the normal range, pointing toward the fourth or fifth toe depending on severity.

Natural History

The natural history of metatarsus adductus is largely favourable. Studies have demonstrated that the majority of cases — estimates range from 85 to 90 percent — resolve spontaneously without any formal intervention by the time the child reaches two to four years of age. The flexibility of the foot at the time of diagnosis is the strongest predictor of spontaneous resolution: flexible deformities almost always self-correct as the child begins to walk and weight-bear, which itself provides a corrective stimulus to the developing foot architecture.

This benign natural course must, however, be balanced against the recognition that a subset of children — particularly those with rigid or severe deformity — will not resolve without treatment. If left untreated, persistent metatarsus adductus can lead to difficulties fitting standard footwear, an abnormal gait pattern, and in some cases, cosmetic and functional concerns in adolescence and adulthood. Early identification and appropriate triage are therefore important.

Management

The management of metatarsus adductus is stratified by severity and flexibility. For mild and moderate flexible cases, the initial recommendation is typically observation and parental reassurance, combined with passive stretching exercises. Parents are instructed to gently manipulate the forefoot outward (abduct) during diaper changes and feeding, holding the stretch for several seconds and repeating multiple times throughout the day. The evidence base for stretching alone is variable, but it is generally considered low-risk and may accelerate resolution.

When the deformity is moderate to severe, or when it fails to improve with observation and stretching by around six months of age, serial casting is the intervention of choice. The foot is placed in a corrective cast that gradually abducts the forefoot over a series of weekly or fortnightly cast changes. Serial casting is most effective when initiated before the age of eight months, when the foot bones are still highly malleable. Results are generally excellent, with the majority of treated children achieving a normal or near-normal foot shape.

For rigid cases that do not respond adequately to casting, or for older children presenting with residual deformity, specialised corrective footwear or custom orthotics may be recommended. Surgical intervention is rarely required and is typically reserved for children over four years of age with significant functional impairment. Surgical options include soft tissue releases or osteotomies (surgical realignment of the metatarsal bones), though the long-term outcomes of surgery for MA are mixed, and most paediatric orthopaedic surgeons advocate conservative management wherever possible.

Differential Diagnosis

It is important to distinguish metatarsus adductus from other causes of in-toeing in children, as the management strategies differ considerably. Skewfoot (also called Z-foot or serpentine foot) is a more complex deformity in which both the forefoot and hindfoot are involved, and it carries a less predictable response to conservative treatment. Clubfoot presents with equinus (downward pointing) of the ankle, heel varus, and midfoot cavus in addition to forefoot adduction, and requires prompt, structured management such as the Ponseti method. Internal tibial torsion and femoral anteversion are other common causes of in-toeing that arise from the leg bones rather than the foot itself and require different assessment and treatment pathways.

Metatarsus adductus is a common congenital foot deformity that, in most cases, resolves naturally as the child grows and develops. Its cause is predominantly positional, stemming from intrauterine crowding in the final stages of pregnancy, though genetic factors also play a role. The severity and flexibility of the deformity at presentation guide clinical management, ranging from watchful waiting and parental stretching exercises to serial casting for more rigid or persistent cases. Surgical intervention is an option of last resort. With timely recognition and appropriate management, the prognosis for children with metatarsus adductus is excellent, and the vast majority can expect a fully functional, normally appearing foot in childhood and beyond.